SAN DIEGO, Sept. 30 /PRNewswire/ — Aethlon Medical, Inc. (OTC
Bulletin Board:
AEMD), the pioneer in developing therapeutic filtration devices
to address infectious disease and cancer, announced today that it
has engaged Fabiani & Company to assist in the establishment of
federal partnerships that advance biodefense, cancer, and chronic
infectious disease applications of the Aethlon Hemopurifier®.
The Aethlon Hemopurifier® is the first medical device to
selectively target the removal of infectious viruses and
immunosuppressive proteins from the entire circulatory system.
Fabiani & Company is a Washington, D.C.-based government
affairs firm founded with the primary goal of providing a select
group of clients creative and innovative strategies to effectively
represent them and their interests before the United States Federal
Government.

(Photo:  http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

“Our colleagues at Fabiani & Company provide us a well
respected presence inside the beltway and increase our likelihood
of accessing non-dilutive resources to advance our endeavors across
multiple disease conditions in the United States,” stated Aethlon
Chairman and CEO, Jim Joyce.  

“We are pleased and excited to partner with Aethlon Medical,”
said Fabiani & Company principal, Stephen Conafay. “Aethlon’s
experienced management team, coupled with their breakthrough
Hemopurifier® technology offers to provide a wide variety of
cancer and immune suppressed patients a minimally invasive
therapeutic strategy at significantly reduced costs when compared
to present therapies.” Additional details can be accesse

‘/>”/>

SOURCE